ESR1 and type 2 diabetes mellitus: Recent studies (Kroker and Bruning, 2015) have shown that some PPARG agonists retain insulin sensitization with few side effects and are widely used in the treatment of type 2 diabetes mellitus; ESR includes ESR1 and ESR2, and most of the effects of oestrogen are mediated by ESR1.